The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities

Table of Contents

Executive Summary

• The macroeconomic environment in the Middle East
• Healthcare systems in the Middle East
• Pharmaceutical market analysis of the Middle East
• Competitive landscape of the Middle Eastern pharmaceutical market
• Scope and Methodology
• Scope
• Methodology

Chapter 1 The macroeconomic environment in the Middle East

• Summary
• Introduction
• Population profile
• Disease burden
• Macroeconomic comparison of the Middle East
• Economic landscape of key Middle Eastern countries
  • Egypt
  • Turkey
  • Saudi Arabia
  • Israel
  • Jordan
  • UAE
  • Lebanon
  • Kuwait

Chapter 2 Healthcare systems in the Middle East

• Summary
• Introduction
• Profiles of the healthcare systems across Middle Eastern countries

• Egypt
  • Healthcare system
  • Intellectual property rights
  • Pricing and reimbursement
  • Key recent events
• Turkey
  • Healthcare system
  • Intellectual property rights
  • Pricing and reimbursement
  • Key recent events
• Saudi Arabia
  • Healthcare system
  • Intellectual property rights
  • Pricing and reimbursement
  • Key recent events
• Israel
  • Healthcare system
  • Intellectual property rights
  • Pricing and reimbursement
  • Key recent events
• Jordan
  • Healthcare system
  • Intellectual property rights
  • Pricing and reimbursement
  • Key recent events
• UAE
  • Healthcare system
  • Intellectual property rights
  • Pricing and reimbursement
  • Key recent events
• Lebanon
  • Healthcare system
  • Intellectual property rights
  • Pricing and reimbursement
  • Key recent events
• Kuwait
  • Healthcare system
  • Intellectual property rights
  • Pricing and reimbursement

Chapter 3 Pharmaceutical Market analysis in the Middle East

• Summary
• Introduction
• Pharmaceutical market overview
• Therapy area analysis
• Therapy area sales forecast
• Therapy area analysis by country

• Egypt
• Turkey
• Saudi Arabia
• Israel
• Jordan
• UAE
• Lebanon
• Kuwait

• Leading brands analysis
  • Seretide (GSK)
  • Lipitor (Pfizer)
  • Augmentin (GSK/MUP)
  • Glivec (Novartis)
  • Co-Diovan (Novartis)
  • Spiriva (Boehringer Ingelheim)
  • Plavix (Sanofi-Aventis)
  • Cipralex (Lundbeck)
  • Lansor (Sanovel)
  • Symbicort (AstraZeneca)
• Leading brands sales forecast

• Key brand analysis by country

• Egypt
  • Flumox and Cefotax (Eipico)
  • Amaryl (Sanofi-Aventis)
  • Cataflam (Novartis)
  • Augmentin (MUP)
• Turkey
  • Foradil Combi (Novartis)
  • Taxotere (Sanofi-Aventis)
  • Herceptin (Roche)
• Saudi Arabia
  • Augmentin (GSK)
  • Snafi (Spimaco)
  • Viagra (Pfizer)
  • Nexium (AstraZeneca)
• Israel
  • Norditropin (Novo Nordisk)
  • Seretide (GSK)
  • Tritace (Sanofi-Aventis)
• Jordan
  • Amoclan (Hikma)
  • Similac Gain and Similac Advance (Abbott Nutrition)
  • Cerelac (Nestle)
• United Arab Emirates
  • Cialis (Eli Lilly)
  • Plavix (Sanofi-Aventis)
  • Zinnat (GSK)
• Lebanon
  • Pariet (J&J)
  • Concor (Merck KGaA)
  • Crestor (AstraZeneca)
• Kuwait
  • Rocephin (Roche)
  • Xenical (Roche)
  • Yasmin (Bayer)

Chapter 4 Competitive landscape of the Middle Eastern pharmaceutical market

• Summary
• Introduction
• Leading players

• Analysis of key players in the Middle East

• Novartis
  • Overview
  • Sales focus by leading drug class
  • Marketed product portfolio
  • Novartis' pipeline focus
  • Strategic growth analysis
• GSK
  • Overview
  • Sales focus by leading drug class
  • Marketed product portfolio
  • GSK' s pipeline focus
  • Strategic growth analysis
• Sanofi-Aventis
  • Overview
  • Sales focus by leading drug class
  • Marketed product portfolio
  • Sanofi-Aventis pipeline focus
  • Strategic growth analysis
• Pfizer
  • Overview
  • Sales focus by leading drug class
  • Marketed product portfolio
  • Pfizer' s pipeline focus
  • Strategic growth analysis
• Ibrahim
  • Overview
  • Sales focus by leading drug class
  • Marketed product portfolio
  • Ibrahim' s pipeline focus
  • Strategic growth analysis

• Leading players analysis by country
  • Egypt
  • Turkey
  • Saudi Arabia
  • Israel
  • Jordan
  • UAE
  • Lebanon
  • Kuwait

Chapter 5 Appendix

• Anatomical therapeutic classification (ATC)
  • A: Alimentary tract and metabolism
  • B: Blood and blood-forming organs
  • C: Cardiovascular system
  • D: Dermatologicals
  • G: Genitourinary system and sex hormones
  • H: Systemic hormonal preparations
  • J: General anti-infectives systemic
  • K: Hospital solutions
  • L: Antineoplastic and immunomodulating agents
  • M: Musculoskeletal system
  • N: Nervous system
  • P: Parasitology
  • R: Respiratory system
  • S: Sensory organs
  • T: Diagnostic agents
  • V: Various
  • Forecast factors
• Glossary
• Index

List of Figures

• Figure 1.1: GDP composition by sector in key Middle East countries, 2008
• Figure 1.2: Comparison of healthcare expenditure across major Middle Eastern countries
• Figure 3.3: Middle East pharmaceutical market share by countries, 2008
• Figure 3.4: Top 10 drug classes in the Egyptian pharmaceutical market, 2008 ($m)
• Figure 3.5: Top 10 drug classes in the Turkish pharmaceutical market, 2008 ($m)
• Figure 3.6: Top 10 drug classes in the Saudi Arabian pharmaceutical market, 2008 ($m)
• Figure 3.7: Top 10 drug classes in the Israel pharmaceutical market, 2008 ($m)
• Figure 3.8: Top 10 drug classes in the Jordanian pharmaceutical market, 2008 ($m)
• Figure 3.9: Top 10 drug classes in the UAE pharmaceutical market, 2008 ($m)
• Figure 3.10: Top 10 drug classes in the Lebanese pharmaceutical market, 2008 ($m)
• Figure 3.11: Top 10 drug classes in the Kuwaiti pharmaceutical market, 2008 ($m)
• Figure 4.12: Market share of top 10 and other players in the Middle East pharmaceutical market, 2008
• Figure 4.13: Novartis' Middle East pharmaceutical market sales by therapy area, 2008
• Figure 4.14: GSK' s Middle East pharmaceutical market sales by therapy area, 2008
• Figure 4.15: Sanofi-Aventis' Middle East pharmaceutical market sales by therapy area, 2008
• Figure 4.16: Pfizer' s Middle East pharmaceutical market sales by therapy area, 2008
• Figure 4.17: Ibrahim' s Middle East pharmaceutical market sales by therapy area, 2008

List of Tables

• Table 1.1: Demographic profile of key Middle East countries
• Table 1.2: Forecast epidemiology of common risk factors in Egypt, 2008 - 14
• Table 1.3: Forecast epidemiology of common risk factors in Turkey, 2008 - 14
• Table 1.4: Forecast epidemiology of common risk factors in Saudi Arabia, 2008 - 14
• Table 1.5: Forecast epidemiology of common risk factors in Israel, 2008 - 14
• Table 1.6: Forecast epidemiology of common risk factors in Jordan, 2008 - 14
• Table 1.7: Forecast epidemiology of common risk factors in UAE, 2008 - 14
• Table 1.8: Forecast epidemiology of common risk factors in Lebanon, 2008 - 14
• Table 1.9: Forecast epidemiology of common risk factors in Kuwait, 2008 - 14
• Table 1.10: Key economic metrics of Middle East countries, 2008
• Table 3.11: Pharmaceutical sales in major Middle East countries, 2008
• Table 3.12: Middle East pharmaceutical sales by therapy area, 2008
• Table 3.13: Middle East pharmaceutical market sales forecast by ATC code, 2008 - 14
• Table 3.14: Egypt' s pharmaceutical market by therapy area sales, 2008
• Table 3.15: Turkey' s pharmaceutical market by therapy area sales, 2008
• Table 3.16: Saudi Arabia' s pharmaceutical market break-down by therapy area sales, 2008
• Table 3.17: Israel' s pharmaceutical market by therapy area sales, 2008
• Table 3.18: Jordan' s pharmaceutical market breakdown by therapy area sales, 2008
• Table 3.19: UAE' s pharmaceutical market by therapy area sales, 2008
• Table 3.20: Lebanon' s pharmaceutical market by therapy area sales, 2008
• Table 3.21: Kuwait' s pharmaceutical market by therapy area sales, 2008
• Table 3.22: Leading brands in the Middle East pharmaceutical market, 2008
• Table 3.23: Leading brand sales forecast, 2008 - 14
• Table 3.24: Leading brands in the Egyptian pharmaceutical market, 2008
• Table 3.25: Leading brands in the Turkish pharmaceutical market, 2008
• Table 3.26: Leading brands in the Saudi Arabian pharmaceutical market, 2008
• Table 3.27: Leading brands in the Israeli pharmaceutical market, 2008
• Table 3.28: Leading brands in the Jordanian pharmaceutical market, 2008
• Table 3.29: Leading brands in the UAE pharmaceutical market, 2008
• Table 3.30: Leading brands in the Lebanese pharmaceutical market, 2008
• Table 3.31: Leading brands in the Kuwaiti pharmaceutical market, 2008
• Table 4.32: Leading companies in the Middle East pharmaceutical market, 2008
• Table 4.33: Novartis' leading brands in the Middle East market, 2008
• Table 4.34: GSK' s leading brands in the Middle East market, 2008
• Table 4.35: Sanofi-Aventis' leading brands in the Middle East market, 2008
• Table 4.36: Pfizer' s leading brands in the Middle East market, 2008
• Table 4.37: Ibrahim' s leading brands in the Middle East market, 2008
• Table 4.38: Leading companies in the Egyptian pharmaceutical market, 2008
• Table 4.39: Leading companies in the Turkish pharmaceutical market, 2008
• Table 4.40: Leading companies in the Saudi Arabian pharmaceutical market, 2008
• Table 4.41: Leading companies in the Israeli pharmaceutical market, 2008
• Table 4.42: Leading companies in the Jordanian pharmaceutical market, 2008
• Table 4.43: Leading companies in the UAE pharmaceutical market, 2008
• Table 4.44: Leading companies in the Lebanese pharmaceutical market, 2008
• Table 4.45: Leading companies in the Kuwaiti pharmaceutical market, 2008